S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:IONS

Ionis Pharmaceuticals - IONS Price Target & Analyst Ratings

$44.26
-1.45 (-3.17%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$42.88
$46.15
50-Day Range
$33.50
$45.71
52-Week Range
$25.04
$46.15
Volume
1.12 million shs
Average Volume
1.09 million shs
Market Capitalization
$6.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.30

Ionis Pharmaceuticals Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 10 Analyst Ratings

Consensus Analyst Price Target

$45.30
2.35% Upside
High Prediction$65.00
Average Prediction$45.30
Low Prediction$26.00
TypeCurrent
8/9/21 to 8/9/22
1 Month Ago
7/10/21 to 7/10/22
3 Months Ago
5/11/21 to 5/11/22
1 Year Ago
8/9/20 to 8/9/21
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
7 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$45.30$43.44$41.88$57.59
Predicted Upside2.35% Upside28.36% Upside24.28% Upside17.36% Upside
Get Ionis Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.


IONS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IONS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ionis Pharmaceuticals Stock vs. The Competition

TypeIonis PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.30
2.71
2.50
Consensus RatingHoldBuyHold
Predicted Upside3.33% Upside570.60% Upside19.18% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
652
61.34%
Underperform Votes
411
38.66%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
840
68.68%
Avg. Underperform Votes
383
31.32%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/26/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$55.00 ➝ $58.00+51.36%
7/18/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$59.00+50.20%
6/21/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$26.00 ➝ $27.00-28.53%
5/5/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$31.00 ➝ $33.00-13.16%
3/1/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$64.00+91.73%
2/28/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell$26.00-22.11%
2/1/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Underperform$40.00 ➝ $30.00-5.66%
12/14/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
12/10/2021BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gary Nachman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00+117.10%
11/4/2021Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$84.00 ➝ $60.00+77.73%
10/12/2021Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight$33.00 ➝ $31.00-9.91%
5/7/2021UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Esther Rajavelu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$33.00 ➝ $37.50+0.46%
3/23/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$52.00 ➝ $47.00-15.53%
3/23/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetPositive ➝ Outperform$76.00 ➝ $65.00+16.82%
12/15/2020Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform
9/22/2020Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$56.00 ➝ $59.00+17.53%
9/14/2020JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
9/2/2020Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
11/7/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tyler Van Buren
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral$75.00 ➝ $70.00+26.33%
10/10/2019Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$90.00 ➝ $120.00+95.06%
9/10/2019Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$80.00+33.07%
(Data available from 8/9/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












IONS Price Target - Frequently Asked Questions

What is Ionis Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Ionis Pharmaceuticals stock is Hold based on the current 3 sell ratings, 1 hold rating and 6 buy ratings for IONS. The average twelve-month price prediction for Ionis Pharmaceuticals is $45.30 with a high price target of $65.00 and a low price target of $26.00. Learn more on IONS's analyst rating history.

Do Wall Street analysts like Ionis Pharmaceuticals more than its competitors?

Analysts like Ionis Pharmaceuticals less than other Medical companies. The consensus rating for Ionis Pharmaceuticals is Hold while the average consensus rating for medical companies is Buy. Learn more on how IONS compares to other companies.

Do MarketBeat users like Ionis Pharmaceuticals more than its competitors?

MarketBeat users like Ionis Pharmaceuticals less than other Medical companies. 61.34% of MarketBeat users gave Ionis Pharmaceuticals an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Does Ionis Pharmaceuticals's stock price have much upside?

According to analysts, Ionis Pharmaceuticals's stock has a predicted upside of 30.00% based on their 12-month price targets.

What analysts cover Ionis Pharmaceuticals?

Ionis Pharmaceuticals has been rated by Oppenheimer, Piper Sandler, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:IONS) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.